BioSpace News Archive

QIAGEN expands QIAstat-Dx syndromic testing menu in the U.S. with launch of molecular test to improve gastrointestinal care

QIAGEN announced the launch of the QIAstat-Dx Gastrointestinal Panel 2 in the United States.

June 3, 2024
·
8 min read
Germans Trias i Pujol Hospital in Spain Launches Telehealth and Remote Patient Management Program Using Masimo W1® Medical Watches and Radius VSM™ Wearable Continuous Vital Signs Monitors

Masimo announced that Germans Trias i Pujol, a pioneering hospital serving more than 800,000 people in north Barcelona, Spain, is launching a breakthrough telehealth and remote patient management initiative using Masimo technology.

June 3, 2024
·
11 min read
Business

Orion is developing the Finnish life science industry in a unique collaboration project

Orion is participating in a project led by the University of Turku for which Business Finland recently granted 11.7M€ funding.

June 3, 2024
·
4 min read
Genetown

SolasCure Selected for Innovate UK Global Incubator Programme in Houston

SOLASCURE Ltd, a biotechnology company developing a novel treatment to transform chronic wound care, announced it has been selected for Innovate UK’s Global Incubator Programme in Houston, US.

June 3, 2024
·
2 min read
Biotech Beach

Skye Bioscience to Present at Jefferies Global Healthcare Conference

Skye Bioscience, Inc. today announced that Chief Executive Officer & Chair, Punit Dhillon, will present an overview of the company and its programs in obesity and glaucoma at the Jefferies Global Healthcare Conference being held in New York City.

June 3, 2024
·
3 min read
Deals

NewGenIvf Signs Non-Binding Term Sheet for Potential Reverse Merger with COVIRIX

NewGenIvf Group, a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, announced the execution of a non-binding term sheet regarding a proposed reverse merger with pharmaceutical company COVIRIX Medical Pty Ltd.

June 3, 2024
·
7 min read
Drug Development

Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024

Alkermes plc announced new data from the full narcolepsy type 1 cohort of a phase 1b, proof-of-concept study evaluating ALKS 2680, the company’s novel, investigational, oral orexin 2 receptor agonist in development as a once-daily treatment for narcolepsy.

June 3, 2024
·
9 min read
Drug Development

IDRx Reports Updated Preliminary Phase 1 Data from Ongoing Phase 1/1b StrateGIST 1 Trial Supporting Best-in-Class Potential for IDRX-42 in Patients with GIST

IDRx, Inc. announced updated preliminary clinical data from the Phase 1 portion of the company’s ongoing StrateGIST 1 study of IDRX-42 in patients with advanced gastrointestinal stromal tumors.

June 3, 2024
·
8 min read
Drug Development

TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at ASCO 2024 Meeting

TriSalus Life Sciences, Inc. announced that data from its Phase 1b PERIO-02 clinical trial was presented in a poster session at the American Society of Clinical Oncology 2024 Annual Meeting, taking place May 31-June 4, 2024, in Chicago, Illinois.

June 3, 2024
·
8 min read
Press Releases

WACKER Opens mRNA Competence Center in Halle an der Saale, Germany

June 3, 2024
·
4 min read